IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
Appointed internationally recognized immuno-oncology expert Dr. Corinne Epperly, M.D., M.P.H., to IN8bio’s Board of Directors
- Appointed internationally recognized immuno-oncology expert Dr. Corinne Epperly, M.D., M.P.H., to IN8bio’s Board of Directors
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today highlighted recent business updates and provided pipeline goals for 2024. - “2023 was a year marked by strong execution for IN8bio.
- Importantly, we are excited that we are seeing in vivo expansion and persistence of allogeneic gamma-delta T cells, now out to 365 days.
- INB-300: Present additional preclinical data demonstrating proof-of-concept for the nsCAR platform targeting CD33 and CD123 at American Association for Cancer Research (AACR) 2024.